Cognitive impairment in gynecologic cancers: A systematic review of current approaches to diagnosis and treatment

Supportive Care in Cancer

Volumn 22, Issue 1, 2014, Pages 279-287

  Craig, Christine D ^a   Monk, Bradley J ^a   Farley, John H ^a   Chase, Dana M ^a  

^a ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Chemotherapy related cognitive impairment; Gynecologic cancer; Treatment and prevention

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; METHYLPHENIDATE; MODAFINIL; PACLITAXEL; QUINONE DERIVATIVE;

CENTRAL NERVOUS SYSTEM; CHEMOTHERAPY RELATED COGNITIVE IMPAIRMENT; COGNITIVE DEFECT; FATIGUE; FEMALE; GYNECOLOGIC CANCER; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

EID: 84890560834     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-2029-7     Document Type: Review

References (71)

1. Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB (2008) Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice Cognitive Workshop. Ann Oncol 19(4):623-629
2. Boykoff N, Moieni M, Subramanian SK (2009) Confronting chemobrain: an in-depth look at survivors' reports of impact on work, social networks, and health care response. J Cancer Surviv 3(4):223-232
3. cancer.org. Chemo brain. http://www.cancer.org/Treatment/ TreatmentsandSideEffects/PhysicalSideEffects/ChemotherapyEffects/chemo-brain. Accessed October, 2012
4. Ahles TA, Saykin AJ (2007) Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 7(3):192-201
5. Kurita GP, Sjogren P, Ekholm O et al (2011) Prevalence and predictors of cognitive dysfunction in opioid-treated patients with cancer: a multinational study. J Clin Oncol 29(10):1297-1303
6. Stavraka C, Ford A, Ghaem-Maghami S et al (2012) A study of symptoms described by ovarian cancer survivors. Gynecol Oncol 125(1):59-64
7. Reid-Arndt SA (2009) Breast cancer and «chemobrain»: the consequences of cognitive difficulties following chemotherapy and the potential for recovery. Mo Med 106(2):127-131
8. Burton CL, Strauss E, Hultsch DF, Hunter MA (2006) Cognitive functioning and everyday problem solving in older adults. Clin Neuropsychol 20(3):432-452
9. Reiriz AB, Reolon GK, Preissler T, et al (2006) Cancer chemotherapy and cognitive function in rodent models: memory impairment induced by cyclophosphamide in mice. Clin Cancer Res;12(16):5000; author reply 5000-1
10. Dietrich J, Han R, Yang Y, Mayer-Proschel M, Noble M (2006) CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 5(7):22
11. Han R, Yang YM, Dietrich J, Luebke A, Mayer-Proschel M, Noble M (2008) Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol 7(4):12
12. Briones TL, Woods J (2011) Chemotherapy-induced cognitive impairment is associated with decreases in cell proliferation and histone modifications. BMC Neurosci 12:124
13. Gangloff A, Hsueh WA, Kesner AL et al (2005) Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel. J Nucl Med 46(11):1866-1871
14. Mayerhofer K, Bodner K, Saletu B et al (2001) Paclitaxel-carboplatin chemotherapy does not cause encephalopathy in patients with ovarian cancer: a prospective EEG mapping study in 28 patients. Anticancer Res 21(1B):803-808
15. Kreukels BP, Schagen SB, Ridderinkhof KR et al (2006) Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: An electrophysiologic study. Clin Breast Cancer 7(1):67-78
16. Cheung YT, Chui WK, Chan A (2012) Neuro-cognitive impairment in breast cancer patients: pharmacological considerations. Crit Rev Oncol Hematol 83(1):99-111
17. Schagen SB, Hamburger HL, Muller MJ, Boogerd W, van Dam FS (2001) Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol 51(2):159-165
18. Madhyastha S, Somayaji SN, Rao MS, Nalini K, Bairy KL (2002) Hippocampal brain amines in methotrexate-induced learning and memory deficit. Can J Physiol Pharmacol 80(11):1076-1084
19. Walker CH, Drew BA, Antoon JW, Kalueff AV, Beckman BS (2012) Neurocognitive effects of chemotherapy and endocrine therapies in the treatment of breast cancer: recent perspectives. Cancer Invest 30(2):135-148
20. Aluise CD, Sultana R, Tangpong J et al (2010) Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction. Adv Exp Med Biol 678:147-156
21. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D (2002) Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 87(1):21-27
22. Pusztai L, Mendoza TR, Reuben JM et al (2004) Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25(3):94-102
23. Penson RT, Kronish K, Duan Z et al (2000) Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer 10(1):33-41
24. Lutgendorf SK, Weinrib AZ, Penedo F et al (2008) Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol 26(29):4820-4827
25. Szelenyi J (2001) Cytokines and the central nervous system. Brain Res Bull 54(4):329-338
26. Tangpong J, Sompol P, Vore M et al (2008) Tumor necrosis factor alpha-mediated nitric oxide production enhances manganese superoxide dismutase nitration and mitochondrial dysfunction in primary neurons: an insight into the role of glial cells. Neuroscience 151(2):622-629
27. Tangpong J, Cole MP, Sultana R et al (2006) Adriamycin-induced, TNF-alpha mediated central nervous system toxicity. Neurobiol Dis 23(1):127-139
28. Joshi G, Sultana R, Tangpong J et al (2005) Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain. Free Radic Res 39(11):1147-1154
29. Konat GW, Kraszpulski M, James I, Zhang HT, Abraham J (2008) Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats. Metab Brain Dis 23(3):325-333
30. Seigers R, Timmermans J, van der Horn HJ et al (2010) Methotrexate reduces hippocampal blood vessel density and activates microglia in rats but does not elevate central cytokine release. Behav Brain Res 207(2):265-272
31. Correa DD, Zhou Q, Thaler HT, Maziarz M, Hurley K, Hensley ML (2010) Cognitive functions in long-term survivors of ovarian cancer. Gynecol Oncol 119(2):366-369
32. Meyers CA (2000) Neurocognitive dysfunction in cancer patients. Oncology (Williston Park).;14(1):75-9; discussion 79, 81-2, 85
33. Meyers CA, Wefel JS (2003) The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol 21(19):3557-3558
34. Suri D, Vaidya VA (2012) Glucocorticoid regulation of brain-derived neurotrophic factor: relevance to hippocampal structural and functional plasticity. Neuroscience
35. Aleman A, Torres-Aleman I (2009) Circulating insulin-like growth factor I and cognitive function: neuromodulation throughout the lifespan. Prog Neurobiol 89(3):256-265
36. Parker WH, Jacoby V, Shoupe D, Rocca W (2009) Effect of bilateral oophorectomy on women's long-term health. Womens Health (Lond Engl) 5(5):565-576
37. Vodermaier A (2009) Breast cancer treatment and cognitive function: the current state of evidence, underlying mechanisms and potential treatments. Womens Health (Lond Engl) 5(5):503-516
38. Loibl S, Lintermans A, Dieudonne AS, Neven P (2011) Management of menopausal symptoms in breast cancer patients. Maturitas 68(2):148-154
39. Dutta V (2011) Chemotherapy, neurotoxicity, and cognitive changes in breast cancer. J Cancer Res Ther 7(3):264-269
40. Hess LM, Chambers SK, Hatch K et al (2010) Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer. J Support Oncol 8(6):252-258
41. Hermelink K, Kuchenhoff H, Untch M et al (2010) Two different sides of 'chemobrain': determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psychooncology 19(12):1321-1328
42. Hensley ML, Correa DD, Thaler H et al (2006) Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning. Gynecol Oncol 102(2):270-277
43. Deprez S, Amant F, Smeets A et al (2012) Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol 30(3):274-281
44. Silverman DH, Dy CJ, Castellon SA et al (2007) Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 103(3):303-311
45. Lower EE, Fleishman S, Cooper A et al (2009) Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage 38(5):650-662
46. Mar Fan HG, Clemons M, Xu W et al (2008) A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 16(6):577-583
47. Kohli S, Fisher SG, Tra Y et al (2009) The effect of modafinil on cognitive function in breast cancer survivors. Cancer 115(12):2605-2616
48. Lundorff LE, Jonsson BH, Sjogren P (2009) Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial. Palliat Med 23(8):731-738
49. O'Shaughnessy JA (2002) Effects of epoetin alfa on cognitive function, mood, asthenia, and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer 3(Suppl 3):S116-S120
50. Fan HG, Park A, Xu W et al (2009) The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer. Psychooncology 18(2):156-161
51. Jatoi A, Kahanic SP, Frytak S et al (2005) Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: preliminary results and suggestions for future study designs. Support Care Cancer 13(1):66-69
52. Chan KK, Yao TJ, Jones B et al (2011) The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring. Ann Oncol 22(10):2241-2249
53. Attia A, Rapp SR, Case LD et al (2012) Phase II study of Ginkgo biloba in irradiated brain tumor patients: effect on cognitive function, quality of life, and mood. J Neurooncol 109(2):357-363
54. Heishman SJ, Kleykamp BA, Singleton EG (2010) Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology (Berl) 210(4):453-469
55. Raffa RB (2011) Cancer 'survivor-care': I. The alpha7 nAChR as potential target for chemotherapy-related cognitive impairment. J Clin Pharm Ther 36(4):437-445
56. Speca M, Carlson LE, Goodey E, Angen M (2000) A randomized, wait-list controlled clinical trial: the effect of a mindfulness meditation-based stress reduction program on mood and symptoms of stress in cancer outpatients. Psychosom Med 62(5):613-622
57. Biegler KA, Chaoul MA, Cohen L (2009) Cancer, cognitive impairment, and meditation. Acta Oncol 48(1):18-26
58. Oh B, Butow PN, Mullan BA et al (2012) Effect of medical qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial. Support Care Cancer 20(6):1235-1242
59. Cohen K (1999) The way of qigong. 1st trade paperback ed. New York: Ballantine Books; 427
60. Galantino ML, Greene L, Daniels L, Dooley B, Muscatello L, O'Donnell L (2012) Longitudinal impact of yoga on chemotherapy-related cognitive impairment and quality of life in women with early stage breast cancer: a case series. Explore (NY) 8(2):127-135
61. Fardell JE, Vardy J, Shah JD, Johnston IN (2012) Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity. Psychopharmacology (Berl) 220(1):183-193
62. Ferguson RJ, McDonald BC, Rocque MA et al (2012) Development of CBT for chemotherapy-related cognitive change: Results of a waitlist control trial. Psychooncology 21(2):176-186
63. Joly F, Rigal O, Noal S, Giffard B (2011) Cognitive dysfunction and cancer: which consequences in terms of disease management? Psychooncology 20(12):1251-1258
64. Mori T, Rezai-Zadeh K, Koyama N et al (2012) Tannic acid is a natural beta-secretase inhibitor that prevents cognitive impairment and mitigates Alzheimer-like pathology in transgenic mice. J Biol Chem 287(9):6912-6927
65. Sattler C, Toro P, Schonknecht P, Schroder J (2012) Cognitive activity, education and socioeconomic status as preventive factors for mild cognitive impairment and Alzheimer's disease. Psychiatry Res 196(1):90-95
66. Fardell JE, Vardy J, Johnston IN, Winocur G (2011) Chemotherapy and cognitive impairment: treatment options. Clin Pharmacol Ther 90(3):366-376
67. Grimmett C, Bridgewater J, Steptoe A, Wardle J (2011) Lifestyle and quality of life in colorectal cancer survivors. Qual Life Res 20(8):1237-1245
68. Scapagnini G, Vasto S, Abraham NG, Caruso C, Zella D, Fabio G (2011) Modulation of Nrf2/ARE pathway by food polyphenols: a nutritional neuroprotective strategy for cognitive and neurodegenerative disorders. Mol Neurobiol 44(2):192-201
69. Hajjar I, Hart M, Chen YL et al (2012) Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Arch Intern Med 172(5):442-444
70. Brinton LA, Sakoda LC, Frederiksen K et al (2007) Relationships of uterine and ovarian tumors to pre-existing chronic conditions. Gynecol Oncol 107(3):487-494
71. Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International cognition and cancer task force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12(7):703-708